Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entity

United Arab Emirates — Emirates Drug Establishment

Tracked across 2 events · 12 articles · First seen Dec 20, 2025 · Last active Jun 02, 2026

Sentiment
70
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
4 70
Tech
Impact: The United Arab Emirates — Emirates Drug Establishment announced the approval of Onasemnogene abeparvovec, demonstrating its commitment to providing patients with advanced genetic therapies and positioning the United Arab Emirates as a regional hub for pharmaceutical innovation.
Dec 20, 2025 · 6 articles
4 70
Regulatory
The United Arab Emirates — Emirates Drug Establishment (EDE) in the United Arab Emirates has approved Semaglutide (semaglutide), an oral once-daily treatment developed by Novo Nordisk, for long-term weight management in adults with obesity or…
Impact: The United Arab Emirates — Emirates Drug Establishment approved Semaglutide (semaglutide) for long-term weight management, reaffirming its commitment to promoting the pharmaceutical ecosystem and addressing obesity challenges.
Jun 01, 2026 · 6 articles
NEWSDESK
Track United Arab Emirates — Emirates Drug Establishment live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.